

Claims

1. Use of an antibody specific for CD19 in the manufacture of a medicament for treating a B cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or B cell acute lymphoblastic leukemia, wherein the medicament is to be administered in combination with Idelalisib, and wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

2. The use according to claim 1, wherein the antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTYNEKFQGRVTISSDKSIS
TAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQGLTVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFT
LTISLSEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

3. The use according to claim 1 or claim 2, wherein the antibody comprises a heavy chain constant domain of the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQ
FNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKISKTKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

4. The use according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain of the sequence
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

5. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and Idelalisib are administered separately.
6. The use according to claim 5, wherein said antibody specific for CD19 and Idelalisib are administered separately physically.
7. The use according to claim 5, wherein said antibody specific for CD19 and Idelalisib are administered separately in time.
8. The use according to any one of claims 1-4, wherein said antibody specific for CD19 and Idelalisib are administered together.
9. The use according to any one of claims 1-4, wherein Idelalisib is administered prior to administration of the antibody specific for CD19.
10. The use according to any one of claims 1-4, wherein Idelalisib is administered after administration of the antibody specific for CD19.
11. The use according to any one of claims 1-4, wherein Idelalisib and the antibody specific for CD19 are administered simultaneously.
12. The use according to any one of the preceding claims for treating a B cell non-Hodgkin's lymphoma, wherein the B cell non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, and mantle cell lymphoma.
13. The use according to any one of the preceding claims for treating chronic lymphocytic leukemia.

14. The use according to any one of the preceding claims for treating B cell acute lymphoblastic leukemia.